PLENAXIS Drug Patent Profile
✉ Email this page to a colleague
When do Plenaxis patents expire, and what generic alternatives are available?
Plenaxis is a drug marketed by Speciality European and is included in one NDA.
The generic ingredient in PLENAXIS is abarelix. Additional details are available on the abarelix profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PLENAXIS?
- What are the global sales for PLENAXIS?
- What is Average Wholesale Price for PLENAXIS?
Summary for PLENAXIS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 45 |
| Clinical Trials: | 3 |
| Patent Applications: | 4,209 |
| DailyMed Link: | PLENAXIS at DailyMed |
Recent Clinical Trials for PLENAXIS
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| PRAECIS Pharmaceuticals Inc. | Phase 4 |
| PRAECIS Pharmaceuticals Inc. | Phase 2 |
| Speciality European Pharma Limited | Phase 3 |
US Patents and Regulatory Information for PLENAXIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Speciality European | PLENAXIS | abarelix | INJECTABLE;INTRAMUSCULAR | 021320-001 | Nov 25, 2003 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PLENAXIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Speciality European | PLENAXIS | abarelix | INJECTABLE;INTRAMUSCULAR | 021320-001 | Nov 25, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| Speciality European | PLENAXIS | abarelix | INJECTABLE;INTRAMUSCULAR | 021320-001 | Nov 25, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| Speciality European | PLENAXIS | abarelix | INJECTABLE;INTRAMUSCULAR | 021320-001 | Nov 25, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| Speciality European | PLENAXIS | abarelix | INJECTABLE;INTRAMUSCULAR | 021320-001 | Nov 25, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| Speciality European | PLENAXIS | abarelix | INJECTABLE;INTRAMUSCULAR | 021320-001 | Nov 25, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PLENAXIS
See the table below for patents covering PLENAXIS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Korea | 20000069432 | ⤷ Sign Up | |
| European Patent Office | 0794961 | PEPTIDES ANTAGONISTES DE LA LHRH (LHRH ANTAGONIST PEPTIDES) | ⤷ Sign Up |
| European Patent Office | 1188768 | Peptides antagonistes de LHRH (LHRH antagonist peptides) | ⤷ Sign Up |
| Austria | 378059 | ⤷ Sign Up | |
| Australia | 735174 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PLENAXIS
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0794961 | CR 2011 00004 | Denmark | ⤷ Sign Up | PRODUCT NAME: ABARELIX, EVENTUELT I FORM AF ET FARMACEUTISK SALT; NAT. REG. NO/DATE: 44637 (DK) 20100827; FIRST REG. NO/DATE: DE 578900000 20050922 |
| 0794961 | CA 2011 00004 | Denmark | ⤷ Sign Up | |
| 0794961 | 1190014-9 | Sweden | ⤷ Sign Up | PRODUCT NAME: ABARELIX |
| 0794961 | SPC/GB11/006 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: ABARELIX, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: DE - 20050922; UK PL32828/001 20100917 |
| 0794961 | C300484 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ABARELIX, EVENTUEEL IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: RVG 104389 20101220; FIRST REGISTRATION: 57890.00.00 20050922 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
